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Abstract
Surveillance data indicate that most circulating A(H1N1)pdm09 influenza viruses have remained antigenically similar since
they emerged in humans in 2009. However, antigenic drift is likely to occur in the future in response to increasing
population immunity induced by infection or vaccination. In this study, sequential passaging of A(H1N1)pdm09 virus by
contact transmission through two independent series of suboptimally vaccinated ferrets resulted in selection of variant
viruses with an amino acid substitution (N156K, H1 numbering without signal peptide; N159K, H3 numbering without signal
peptide; N173K, H1 numbering from first methionine) in a known antigenic site of the viral HA. The N156K HA variant
replicated and transmitted efficiently between naı¨ve ferrets and outgrew wildtype virus in vivo in ferrets in the presence and
absence of immune pressure. In vitro, in a range of cell culture systems, the N156K variant rapidly adapted, acquiring
additional mutations in the viral HA that also potentially affected antigenic properties. The N156K escape mutant was
antigenically distinct from wildtype virus as shown by binding of HA-specific antibodies. Glycan binding assays
demonstrated the N156K escape mutant had altered receptor binding preferences compared to wildtype virus, which was
supported by computational modeling predictions. The N156K substitution, and culture adaptations, have been detected in
human A(H1N1)pdm09 viruses with N156K preferentially reported in sequences from original clinical samples rather than
cultured isolates. This study demonstrates the ability of the A(H1N1)pdm09 virus to undergo rapid antigenic change to
evade a low level vaccine response, while remaining fit in a ferret transmission model of immunization and infection.
Furthermore, the potential changes in receptor binding properties that accompany antigenic changes highlight the
importance of routine characterization of clinical samples in human A(H1N1)pdm09 influenza surveillance.
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Introduction
The first influenza pandemic of the 21st century began in
March 2009 with the emergence of a new swine-origin virus
(A(H1N1)pdm09) which replaced the previous seasonal A(H1N1)
[1]. Surveillance of circulating A(H1N1)pdm09 viruses has
revealed some genetic variation in the hemagglutinin (HA) and
neuraminidase (NA), but no significant antigenic changes have
occurred over the past four years [2]. Moreover, the most recent
circulating A(H1N1)pdm09 viruses remain antigenically closely
related to the 2009 vaccine strain, A/California/7/2009 [3].
Serological studies estimated that during the first wave of infection
in 2009, 34–43% of school-aged children and about 10% of adults
were infected by A(H1N1)pdm09 viruses [4]. This level of natural
exposure, combined with extensive vaccination and the ongoing
circulation of these viruses since 2009, has established widespread
immunity against the A(H1N1)pdm09 virus in the human
population.
Influenza A viruses undergo continuous antigenic variation,
ensuring efficient replication in the human host in the face of
previous vaccination and/or infection (reviewed in [5]). Antigenic
drift involves amino acid changes in antigenic regions of influenza
proteins, facilitating escape from existing immunity. Drift muta-
tions most commonly occur in the gene encoding the HA surface
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glycoprotein, which is the major target of neutralizing antibodies
elicited as a result of vaccination and/or natural infection.
Mutations are typically localized to antigenic sites surrounding
the receptor binding site on the globular head of HA ([6–10],
reviewed in [11]), consistent with the critical role of HA in binding
to cell-surface receptors to initiate infection of respiratory epithelial
cells.
A limited number of in vivo and in vitro studies have attempted to
select influenza virus mutants in the presence of neutralizing
antibodies [12–16]. A(H1N1), A(H3N8) and A(H3N2) viruses have
been passaged multiple times through immunized mice [13] and
once through dogs [14] and guinea pigs [17], respectively.
A(H1N1)pdm09 virus has been cultured in embryonated hen’s
eggs in the presence of mouse monoclonal antibodies [16] or in
MDCK cells in the presence of a human monoclonal antibody
[15]. Resulting ‘immune escape mutants’ often express mutations
that are closely linked with changes in HA receptor binding
specificity and avidity for cell surface receptors [13,16]. Immune
pressure has also been shown to affect viral diversity [14,18]. The
selection of immune escape mutants in the presence of neutralizing
antibodies has been proposed as a major factor driving evolution
of HA in human influenza viruses. Early models proposed that
passage of virus through individuals with different antibody
specificities may induce sequential changes in antigenic regions,
resulting in antigenic drift [19,20]. More recently it has been
postulated that alteration in the HA binding avidity for cell surface
receptors drives antigenic drift and can occur independently, or,
alongside variation in antigenicity as virus is passaged alternately
through partially immune and naı¨ve individuals [13].
Epithelial cells lining the airways of humans and ferrets express
a similar pattern of sialylated receptors, enabling human influenza
viruses to infect ferrets directly [21]. Following influenza infection,
ferrets display similar disease symptoms and pathology to those
observed in humans [22,23]. Multiple immunizations with human
influenza vaccines and adjuvant can protect ferrets from
subsequent upper respiratory tract challenge with influenza virus
[24]. In the absence of adjuvant, immunization with human
influenza vaccine does not result in sterilizing immunity but
significantly reduces viral load in the lower respiratory tract [25].
Serum from influenza-infected ferrets is commonly used in
surveillance to assess antigenicity of influenza viruses circulating
in the human population [26]. In this study, an A(H1N1)pdm09
virus A/Tasmania/2004/2009 was passaged by contact transmis-
sion in ferrets immunized with human A(H1N1)pdm09 vaccine
and adjuvant. An antigenic escape mutant with altered receptor
binding specificity emerged in two independent experiments. This
escape mutant, which has also been detected in human
surveillance studies, was difficult to detect and isolate using
conventional in vitro methods.
Results
A(H1N1)pdm09 virus can transmit between ferrets in the
presence of specific antibodies
A model of influenza transmission under immune pressure was
established by suboptimal immunization of ferrets with the human
monovalent A(H1N1)pdm09 influenza vaccine with adjuvant
(MIV+IFA) or vaccine alone (MIV). A single immunization of
human influenza vaccine with adjuvant does not induce sterilizing
immunity in ferrets ([24] and data not shown). All animals
immunized once with MIV+IFA had serum antibody titres $40
(geometric mean titre [GMT] 332) (measured by hemagglutina-
tion inhibition, HI), while only 31% of animals immunized twice
with MIV had HI titres $40 (GMT 10) (Table 1). In preliminary
experiments, we established that the A(H1N1)pdm09 virus A/
Tasmania/2004/2009 was antigenically indistinguishable from
the vaccine strain A/California/7/2009 by HI assay and grew to
high titres in both the upper and lower respiratory tract of naı¨ve
ferrets (data not shown). Although gene sequencing detected five
amino acid differences between the HA of A/Tasmania/2004/
2009 (GISAID EPI_ISL_129743) and A/California/7/2009
(GenBank: CY058519) (N38N/S, P83S, S203T, T209K, I321V,
Table 2), none were in the major antigenic regions. Amino acids
in HA are referenced using H1 numbering without the signal
peptide [27] in this manuscript.
We examined transmission of A/Tasmania/2004/2009 follow-
ing intranasal inoculation of naı¨ve ferrets or ferrets immunized
with adjuvant and vehicle (PBS+IFA), MIV, or MIV+IFA
(Figure 1 and Figure S1). In each passage line, we examined
seven transmission events and confirmed effective transmission by
detection of virus in nasal washes as described in Materials and
Methods. Contact transmission failed twice for both MIV+IFA
passage lines (Figure 1 and Figure S1). In the first instance this
could be attributed to difficulty in detecting shed virus using an
influenza rapid test (Figure 1 R1–R2(1); Figure S1 R0–R1(1)),
so virus shedding in this group was subsequently assayed by daily
real time RT-PCR. Transmission was restarted artificially by
direct intranasal inoculation of a new recipient ferret with the
nasal wash from the previously infected ferret. The second
transmission failure (R5–R6(1)), detected using real time RT-
PCR, was not due to high immunization antibody titre (data not
shown) and transmission was also restarted as described.
The virus kinetics in all passage lines was assessed using real
time RT-PCR to determine the relative copy number. There was
no difference in the peak viral load achieved in naturally infected
ferrets from any of the groups (Figure 2A). However growth rate
of virus in the ferrets from the MIV+IFA passage lines was
significantly lower compared to naı¨ve and PBS+IFA-immunized
ferrets (20.83 log10 copy number/100 ml/day (p = 0.049) and
21.3 log10 copy number/100 ml/day (p,0.001), respectively). The
growth rate of virus in the ferrets from the MIV passage line was
Author Summary
Infection with influenza virus leads to significant morbidity
and mortality. Annual vaccination may prevent subse-
quent disease by inducing neutralizing antibodies to
currently circulating strains in the human population. To
escape this antibody response, influenza A viruses under-
go continuous genetic variation as they replicate, enabling
viruses with advantageous antigenic mutations to spread
and cause disease in naı¨ve or previously immune or
vaccinated individuals. To date, the 2009 pandemic virus
(A(H1N1)pdm09) has not undergone significant antigenic
drift, with the result that the vaccine remains well-matched
and should provide good protection to A(H1N1)pdm09
circulating viruses. In this study, we induced antigenic drift
in an A(H1N1)pdm09 virus in the ferret model. A single
amino acid mutation emerged in the dominant surface
glycoprotein, hemagglutinin, which had a multifaceted
effect, altering both antigenicity and virus receptor
specificity. The mutant virus could not be isolated using
routine cell culture methods without the virus acquiring
additional amino acid changes, yet was fit in vivo. The
implications for surveillance of circulating influenza virus
are significant as current assays commonly used to assess
vaccine mismatch, as well as to produce isolates for
vaccine manufacture, are biased against identification of
viruses containing only this mutation.
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also significantly lower compared to the PBS+IFA-immunized
ferrets (20.77 log10 copy number/100 ml/day (p = 0.049))
(Figure 2B). The time between transmission events (serial
interval) was longer for the MIV+IFA line (5.3 days) compared
to all other lines (naı¨ve 3.6 days (p = 0.001); PBS+IFA 3.8 days
(p = 0.010); MIV 3.9 days (p = 0.011)) (Figure 2C). Within each
passage line, there was no significant change in any of the kinetics
measurements as passaging progressed, suggesting that the growth
characteristics and transmissibility of the virus remained stable
over time (data not shown).
Emergence and persistence of a mutation in the HA1
protein in a known antigenic site following passaging of
A(H1N1)pdm09 virus in immunized ferrets
RNA was extracted from nasal wash samples from the peak day
of virus shedding and infection (as determined by real time RT-
PCR) for genetic analysis. Once a mutation appeared in the HA or
NA proteins from a ferret of any passage line, it persisted and was
transmitted to all subsequent ferrets. Following inoculation of
donor ferrets (D0) with egg-grown A/Tasmania/2004/2009, we
detected amino acid substitutions in the HA at residues 191
(L191I) and 223 (R223Q) (Table 2). The same mutations were
also detected following passage of another egg-grown
A(H1N1)pdm09 virus (A/Auckland/1/2009) in ferrets (data not
shown). Of interest, mutations that alter residues 191 and 223 have
been associated with host specificity and receptor binding [28,29].
Additional mutations that became fixed in the HA protein were
specific to each passage line. Mutations arose in the naı¨ve passage
lines (G131S, D187E, Table 2) and in the MIV passage line
(D187V, Table 2). G131S creates a potential glycosylation site
and D187 has been associated with host specificity [30,31]. The
G131S, D187E and D187V viruses were antigenically indistin-
guishable from the wildtype virus in HI assays with serum from
ferrets infected with egg-grown A/Tasmania/2004/2009 (data not
shown). D14E, identified in one of the MIV+IFA passage lines, lies
outside predicted antigenic sites [31], does not alter glycosylation
and was not tested further.
The N156K mutation arose in both passage lines of MIV+IFA-
immunized ferrets (Table 2). Position 156 of HA is in antigenic
site Sb [6] (Sa in [31]) (Figure 3C, D). The relative proportions of
the N156K mutant and wildtype N156 viruses were quantified in
Table 1. Serological responses following vaccination and infection.
A/Tasmania/2004/2009 Pre-contact transmissiona Post-contact transmissionb
HI titres % HI titre $40 GMT (95% CI) % HI titre $40 GMT (95% CI)
Naı¨ve (n = 16) 0 5 56 73 (19, 280)
MIV (n = 16) 31 10 (6, 19) 62.5 84 (27, 263)
PBS+IFA (n = 16) 0 5 69 80 (25, 257)
MIV+IFA (n = 20) 100 332 (184, 597) 100 1114 (405, 3068)
a3–13 weeks following last immunization.
bat least 3 days after detection of influenza virus in nasal wash by real time RT-PCR.
doi:10.1371/journal.ppat.1003354.t001
Table 2. Full genome sequencing of inoculum and influenza virus from peak day nasal wash of all R7 ferrets.
Comparison to MIV HA NA M NP NS PB1 PB2 PA
A/Tasmania/2004/2009
inoculuma
N38N/Sb, P83Sb, S203Tb,
T209Kb, I321Vb
V106Ib,
N248Db,
S388Tb
V100Ib I123Vb K312Rb,
N556Sb
P224Sb
NAI¨VE A R7 G131S, L191I, R223Q D87N
NAI¨VE B R7 D187E, L191I, R223Q M66I
MIV A R7 D187V, L191I, R223Q M15I D87N
MIV B R7 L191I, R223Q A643V,
K691N
R293M
PBS+IFA A R7 L191I, R223Q P69P/A R251K R254R/Q
PBS+IFA B R7 L191I, R223Q H214Y D60N
MIV+IFA A R7 D14E, N156K, L191I,
R223Q
D21G (M2) S3Fc N348S,
M410V
MIV+IFA B R7 N156K, L191I, R223Q I46F
N156K Naı¨ve A R7 D14E, N156K, L191I,
R223Q
D21G (M2),
I28T (M2)
S3Fc,
M239V
N348S,
M410V
N156K Naı¨ve B R7 K142N, N156K, L191I, R223Q I46F
aDifferences between inoculum and vaccine strain, A/California/7/2009, are indicated.
bThese mutations persisted in all ferrets, and are removed from R7 samples for clarity of Table.
cNuclear localization signal.
doi:10.1371/journal.ppat.1003354.t002
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samples from both passage lines of MIV+IFA-immunized ferrets
using a pyrosequencing assay. The N156K mutant emerged in R4
of line A, persisted at a similar proportion in R5, and became
dominant by R6. In line B, the N156K mutant emerged earlier, in
R1, and became dominant in R2, persisting through to R7
(Figure 2D). The emergence of the N156K mutation did not
result in a change of virus kinetics (peak viral load, growth rate or
serial interval) compared to N156 wildtype virus (data not shown).
To confirm the pyrosequencing data and to determine whether
the N156K mutation was present in the original inoculum, the
proportion of the N156K mutant was quantified by cloning and
sequencing the HA1 gene from the original inoculum (n = 480)
and from samples from the R7 ferret in each passage line, and the
ferrets in which the N156K mutation was first detected (MIV+IFA
R4, line A and R1, line B) (n = 96 for each) (Table S1). N156K
was detected only in virus samples collected from ferrets in the
MIV+IFA immunization group; proportions were similar by
cloning and pyrosequencing assay (Figure 2D and Table S1). All
mutations detected in the original sequencing were also detected
by cloning. Cloning revealed that L191 and R223 were mixed
populations (L191L/I and R223R/Q) in the original inoculum.
Two mutations were detected in the NA protein: M15I emerged
in the MIV passage line A and I46F in the MIV+IFA passage line
B (Table 2). Residue 15 is located in the N-terminus, while
residue 46 is located in the stalk of the NA, therefore both
substitutions are well outside the enzymatic site of the NA protein
[32]. Full genome sequencing of R7 samples from all passage lines
detected isolated changes in some genes (e.g. M, NP, PB1, PB2,
PA), but none of these substitutions were in known determinants of
virulence and/or transmission (Table 2).
N156K A/Tasmania/2004/2009 HA mutant virus is fit in
naı¨ve ferrets
To assess the ability of the N156K mutant virus to transmit and
persist in vivo, N156K variant viruses (from MIV+IFA R7 ferrets)
were passaged a further seven times by contact transmission in
naı¨ve ferrets (passage lines N156K naı¨ve A and B). The serial
interval between transmission events was similar for wildtype and
N156K virus passaged in naı¨ve ferrets (Figure 2C). Transmission
proceeded without interruption (Figure S2) and both viral growth
rate (Figure 2B) and peak viral loads (Figure 2A) were similar.
Genetic analysis found no changes in the HA protein of virus
isolated from the R7 ferret of N156K line A compared to
inoculum (D14E+N156K). However, an additional mutation was
detected (K142N in R4) and became fixed in the HA of passage
line B (K142N+N156K, Table 2). Position 142 of HA is in
antigenic site Ca2 [6,31] (Figure 3C, D). K142N is not predicted
to alter glycosylation. Full genome analysis found no other
Figure 1. Time course of influenza transmission through passage lines. Naı¨ve donor 0 (D0) ferrets were directly infected with A/Tasmania/
2007/2009 virus and co-housed with naı¨ve donor 1 (D1) ferrets to begin the contact transmission model. D0 and D1 ferrets were not included in any
experimental group. Once D1 was infected, D0 was removed and a ferret from one of the four experimental groups was added (R0). Transmission
then proceeded through R0–R7 ferrets for each group. Line A of each group is shown. The same D0 and D1 ferrets were used to establish the passage
line A of the naı¨ve and MIV experimental groups. The same D0 ferret infected two different D1 ferrets to establish the passage line A of the PBS+IFA
and MIV+IFA experimental groups. Nasal washes were collected daily from ferrets and virus load was measured by real time RT-PCR. During the
experiment, both the rapid test result (PBS+IFA, MIV+IFA day 0–26) and the raw Ct value (naı¨ve, MIV, MIV+IFA day 27 onwards) were used as a marker
of infection and transmission. The data points at which transmission of virus to recipient ferrets was deemed to have occurred are identified as red
symbols. Direct intranasal inoculation indicated by arrow.
doi:10.1371/journal.ppat.1003354.g001
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significant changes (Table 2). In both lines, pyrosequencing and
sequencing of clones showed N156K persisted at approximately
100% in each sample and did not revert to wildtype N156
(Figure 2E, Tables 2, S1). The introduction of the K142N
mutation did not result in a change of virus kinetics peak viral
load, growth rate or serial interval) compared to N156K alone
virus (data not shown).
To directly compare the fitness of the wildtype, N156K and
K142N+N156K viruses in the absence of immune pressure [33],
naı¨ve ferrets were infected with mixtures of either N156 wildtype
and N156K viruses (42:58% ratio from line B R1 (Figure 2D,
and Table S1, MIV+IFA B R1)) or N156K and K142N+N156K
viruses (76:24% ratio by pyrosequencing). Directly infected naı¨ve
ferrets were co-housed with naı¨ve recipients and two transmission
events occurred as before. The N156K virus outgrew the N156
wildtype virus after one or two transmission events, in duplicate
experiments (Figure 2F), as in the original experiment
(Figure 2D). The K142N+N156K virus outgrew the N156K
virus after one or two transmission events (Figure 2G). This
suggests that the N156K variant fitter than the N156 wildtype
virus in the ferret model. It also suggests that the K142N mutation,
when added to N156K, gives a selective advantage. However, as
the K142N mutation was acquired in only one of the two lines of
passaging the N156K virus seven times in naı¨ve ferrets (Table
S1), it is not essential for replication and transmission in the ferret
model.
The N156K A/Tasmania/2004/2009 HA mutant virus does
not agglutinate red blood cells and adapts rapidly in vitro
The HA of human influenza viruses preferentially interacts with
receptors terminated with Neu5Aca-2,6-linked to galactose
Figure 2. Virus replication and transmission kinetics in ferret passage lines and emergence and persistence of the N156K mutant.
(A–C) Nasal washes were collected daily from ferrets from passage lines (R0–R7) and assayed for viral RNA by real time RT-PCR as a measure of
infection and transmission. (A) The peak viral load detected in the nasal wash from each ferret, (B) the viral growth rate ((peak virus load – first day
virus load)/days to reach peak) and (C) the serial interval of virus transmission between ferrets (number of days between detection of infected and
infecting animals) were determined for each immunization line. Ferrets artificially infected by intranasal virus inoculation are not included. Ferrets that
failed to be naturally infected by contact transmission are indicated in white circles. Statistics do not include ferrets that failed to be naturally
infected. (D–E) The proportion of N156 wildtype (black) and N156K (white) viruses in peak day nasal wash samples from all ferrets from the MIV+IFA
(D) and N156K naı¨ve (E) passage lines quantified by pyrosequencing. (F–G) Mixtures of (F) N156 wildtype and N156K or (G) N156K and K142N+N156K
viruses were passaged by contact transmission through naı¨ve ferrets. The proportion of N156 wildtype (black), N156K (white) or K142N+N156K
(striped) in peak day nasal wash samples was quantified by pyrosequencing.
doi:10.1371/journal.ppat.1003354.g002
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(reviewed in [34,35]) and ferret lung epithelial cells predominantly
express a-2,6-linked Neu5Ac residues [21]. As MDCK-SIAT1
cells have enhanced levels of a-2,6-linked Neu5Ac receptors [36],
as confirmed by flow cytometry (data not shown), this cell line was
used first for virus isolation. Isolates from naı¨ve, PBS+IFA and
MIV passage lines were detected in culture supernatants at high
titres by agglutination of turkey RBC (HA.128). However,
isolates from ferrets of the MIV+IFA and N156K naı¨ve passage
lines (herein referred to as N156K mutant virus) had only low
hemagglutination titres (HA#4). Real time RT-PCR for the
matrix gene indicated that levels of viral RNA in the N156K
mutant virus culture supernatant at 72 h post-infection were
similar to those in control samples from naı¨ve or PBS+IFA-
immunized ferrets (herein referred to as wildtype viruses)
(Figure 3A, P1). HA and matrix protein were also detected on
the surface of N156K-infected cells (Figure 3A) and CPE was
visible (data not shown), indicating that N156K mutant virus was
present, even in the absence of RBC agglutination. Use of RBC
from other species (rat, ferret, guinea pig, sheep), or resialylated
RBC, or concentrated culture supernatant did not improve
sensitivity in hemagglutination assays (data not shown). Upon
further passage in MDCK-SIAT1 cells, the N156K mutant virus
was detected only at high HA titres (HA$16) when additional HA
mutations were present (Figure 3A, P2). As folding of the mutated
Figure 3. Growth, detection and adaptation of N156K virus in cell cultures. (A) Virus underwent two passages in MDCK-SIAT1 cells (P1 and
P2). Supernatant was collected during both passages, at 24, 48 and 72 h, and virus load was quantified by real time RT-PCR and hemagglutination
(HAU). Infected cells were also harvested at 48 h and surface HA and M protein expression measured by flow cytometry. Cell culture adaptations
detected by sequencing in the HA protein are shown in each graph. No adaptations in NA were detected. (B) Virus underwent two passages (P1 and
P2) in the indicated cell lines. Virus load was quantified in supernatant as above, and cell culture adaptation was detected by sequencing the HA
protein as indicated. Limit of detection is 103.8 copies. (C) Location of HA mutations in antigenic regions identified in this study. Visualization of
mutation positions relative to classical antigenic sites [6] are shown as colored bubbles (Sa – red; Sb – green; Ca1 – cyan; Ca2 – blue; Cb – yellow). Pink
balls indicate a bound host receptor ligand (a-2,6-linked); white balls indicate sugars on glycosylation sites. (D) Location of antigenic sites in HA
trimer, top and side view, respectively.
doi:10.1371/journal.ppat.1003354.g003
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HA protein may be temperature dependent [37,38], infection and
culture of MDCK-SIAT1 cells with N156K mutant viruses was
also attempted at different temperatures (33, 35 and 37uC), yet
similar cell culture adaptations in the HA protein were observed
(data not shown). Infection and culture were also attempted in the
presence of exogenous neuraminidase or oseltamivir carboxylate
as changes in HA have been shown to affect the HA/NA balance
and influence hemagglutination and isolation in different in vitro
culture systems [39]. N156K was not able to be isolated without
culture adaptations in the presence of exogenous neuraminidase,
or oseltamivir carboxylate (data not shown). Addition of
oseltamivir carboxylate did not improve hemagglutination titres
for N156K either (data not shown), indicating no binding effect of
the NA [39].
Culture adaptations of the HA protein were detected at residues
153, 155 and 156, most commonly as a mixed population at
position 156 (N156K/E) or with mutations at positions 153 or 155
in addition to N156K (K153E+N156K or G155E+N156K)
(Figure 3A, Table 3). Culture adaptations were also seen in
antigenic sites Sa and Sb (Figure 3C, D). These adaptations were
not detected by clonal analysis in the nasal washes from R7 ferrets
of any passage line, in the R4 or R1 ferrets of MIV+IFA passage
lines A and B respectively, or in the original virus inoculum
(Table S1). Culture of virus from peak day samples containing
mixed populations of wildtype (N156) and N156K viruses resulted
in outgrowth of the wildtype N156 virus as determined by RNA
extraction and sequencing (data not shown). No MDCK-SIAT1
culture adaptations were detected in the NA gene.
Attempts to isolate the N156K mutant virus in a variety of other
cell lines (MDCK, Beas-2B, Vero, A549) as well as embryonated
hen’s eggs, were unsuccessful. The virus either did not grow, or it
grew and was detected by real time RT-PCR, but rapidly adapted
in the HA at amino acids 153–156 (Figure 3B).
Attempts were also made to purify virus by ultracentrifugation
from ferret bronchoalveolar lavage and homogenized lung
samples, but this did not yield sufficient virus for analysis.
Detection of N156K and culture adaptations in influenza
surveillance data
The N156K mutation has been detected in human
A(H1N1)pdm09 clinical samples (analyzed for surveillance pur-
poses at the WHO Collaborating Centre for Reference and
Research on Influenza, Melbourne), both alone and in conjunc-
tion with N125D, which is located in antigenic site Sa [6,40] )
(Table 3 and Figure 3C, D). N156D has been detected following
passage of A(H1N1)pdm09 virus in embryonated hen’s eggs under
immune pressure [16]. Mutations at G155 and K153 have been
reported following in vitro passage of A(H1N1)pdm09 viruses in the
absence [29] and presence of monoclonal antibodies (mAbs)
[15,16]. Cell culture adaptations have also been detected in
routine surveillance at the WHO Collaborating Centre for
Influenza, Melbourne, when passaging A(H1N1)pdm09 viruses
with mutations at N156 (Table 3). Analysis of all A(H1N1)pdm09
sequences from 2009–2012 in GISAID and GenBank found
N156K, K153E and N156D at similar low frequencies (0.15, 0.20
and 0.27%, respectively); G155E has been reported more often
(1.30%, Table 4). Among 8446 A(H1N1)pdm09 HA sequences
with classifiable passage information, most were MDCK cell
isolates (69%) followed by original clinical samples (18%), MDCK-
SIAT1 isolates (8%) and embryonated hen’s egg isolates (5%).
There is no change in isolation patterns in each year (2009–2012,
data not shown). The N156K mutation was found more
commonly in original specimens than in cell isolates. In contrast,
K153E and G155E adaptations were strongly associated with
growth in MDCK cells (Table 4).
Cell culture adaptations may disguise the effect of N156K
on the antigenic profile of A/Tasmania/2004/2009 virus
Other in vitro studies have demonstrated that mutations at
amino acids 153, 155 and 156 of A(H1N1)pdm09 HA1 result in
antigenic drift with a reduction in HI titre to the mAbs used to
induce changes in the antigenic sites [15,16] and to serum from
wildtype A(H1N1)pdm09-infected ferrets [29]. Adaptations
K153E and G155E are also antigenically distinct from each other
[16]. We generated viruses containing the HA mutation(s) detected
in our experiments by reverse genetics. All reverse genetics viruses
used contained the ferret-specific adaptations L191I and R223Q
in the HA protein. Neither the N156K alone nor K142N+N156K
virus could be rescued as a pure population without adaptation.
Rescues were attempted with both an A(H1N1) (A/PuertoRico/
8/1934) and an A(H1N1)pdm09 (A/Perth/261/2009) complete
backbone and were also attempted with ‘humanized’ vectors
containing receptors L191 and Q223, but neither was successful
(data not shown). Antigenic analysis by HI assay showed a
reduction in HI titre for all reverse genetics viruses with mutations
at positions 153–156, against serum from a ferret infected with the
original inoculum of A/Tasmania/2004/2009 virus, compared to
wildtype virus. Both reverse genetics mutant N156E as well as
surveillance viruses with mutations and adaptations at N156
showed reduced HI titre compared to wildtype virus, indicating
the antigenic importance of amino acid 156. The K142N
mutation had no effect (Table 5).
All reverse genetics viruses were also tested against serum from a
ferret immunized once with MIV+IFA. All viruses containing
mutations at positions 153–156 showed a four-fold reduction in
titre compared to wildtype virus. Although the K142N mutation
on its own had no effect, addition of this mutation to viruses with
mutation/s at positions 153–156 reduced their titre at least four-
fold further (Table 5).
The HA antigenicity and receptor binding profile are
altered in the N156K A/Tasmania/2004/2009 HA mutant
virus
Our observation that N156K mutant viruses were not detected
by hemagglutination and did not persist without adaptation in vitro
suggested an alteration in receptor binding specificity. N156K and
K142N (and K153E, R223Q) are located in regions on the HA
protein proposed to contact sugars beyond Neu5Ac on cell surface
receptors [28]. Thus we hypothesized that these mutations altered
not only antigenicity but also receptor binding compared to
wildtype virus.
HA structure was investigated by flow cytometry [41] using
mAb174 and mAb175, which are specific for the Sa/Sb (K153
and G155) and Cb (T72) antigenic regions of the A(H1N1)pdm09
virus HA, respectively. All A(H1N1)pdm09 wildtype and variant
viruses were recognized by mAb175 (Figure 4A). The A/
Tasmania/2004/2009 original inoculum and ferret-adapted wild-
type viruses were recognized by mAb174, but binding was greatly
reduced in the presence of the N156K mutation and cell culture
adaptations (Figure 4A). This effect was specific for viruses with
mutations in the Sa/Sb antigenic region as the virus with K142N
mutation alone was still recognized by mAb174.
Direct binding assays using antisera from immunized and virus-
infected ferrets were used to assess the antigenicity of the N156K
mutant virus. Antisera from MIV2, MIV+IFA-immunized ferrets
or from ferrets infected with wildtype virus recognized cells
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infected with N156K virus less efficiently than cells infected with
wildtype virus. In contrast, post-infection antisera from ferrets
infected with N156K or K142N+N156K viruses bound cells
infected with wildtype or N156K mutant virus to a similar degree
(Figure 4B). These data suggest that the N156K virus is
antigenically distinct from wildtype virus. Furthermore, it is likely
Table 4. Analysis of passage history of surveillance viruses with mutations in key residues of HA1 as reported on GISAID and
GenBank.
Passage history Odds Ratio (mutant vs wildtype)
Mutation
No.
reporteda
No. isolates (mutant/
wildtype)b
Total frequency
(%)c Egg isolate
MDCK cell
isolate
MDCK-SIAT1
cell isolate
Original
clinical
sample
N125D 581 321/7730 3.99 2.05 0.96 0.57 1.04
K153E 19 16/8018 0.20 1.59 6.55 - -
G155E 133 103/7827 1.30 0.46 4.63 0.68 0.05
N156D 31 22/7980 0.27 - 4.32 0.52 0.22
N156K 22 12/7980 0.15 - 0.43 1.00 3.28
L191I 47 25/8008 0.31 55.31 0.20 - -
Q223R 133 71/7966 0.88 564.42 0.02 0.00 0.00
The odds ratio, indicating strength of association to passage history, for mutant versus wildtype virus is indicated. Mutations with ,10 samples with any passage
information were omitted (e.g. K156E). (-) indicates that 10–30 records with passage information were available, and no reports were indicated in this passage history.
aOccurrence of mutation in all 16740 A(H1N1)pdm09 sequences on GISAID and/or Genbank, regardless of passage history up to December 2012.
bOccurrence of mutant or wildtype in all A(H1N1)pdm09 sequences on GISAID with passage history information.
c% Occurrence of mutant in all A(H1N1)pdm09 sequences on GISAID with passage history information.
doi:10.1371/journal.ppat.1003354.t004
Table 5. Antigenic analysis of mutations in the HA protein from amino acid 153–156.
Hemagglutination Inhibition titre Sera
Virus source and passage history Virus Wildtypea MIV+IFAb
Virus Reverse genetics ferret-adapted
A/Tasmania/2004/2009 HA (L191I, R223Q)
and NA, MDCK-SIAT1 passagedc
Wildtype 5120 640
K153E 160 160
K153E+N156K 160 160
G155E 160 160
G155E+N156K 160 160
N156E 320 160
K153E+N156E 320 160
G155E+N156E 80 160
K142N 10240 640
K142N+K153E+N156K 160 20
K142N+G155E+N156K 80 20
K142N+N156E 160 40
K142N+G155E+N156E 80 20
Egg passaged A/Tasmania/2004/2009 5120 640
Egg passaged, split Monovalent human vaccine 10240 640
MDCK-SIAT1 passage A/Tasmania/2004/2009 5120 320
Surveillance A(H1N1)pdm09 viruses with
mutation at antigenic sites of HA, MDCK passage
A/Victoria/906/2010 (N125D, N156K/E) 320 320
A/Tasmania/16/2011 (N156N/K/D/E) 160 80
A/Wellington/94/2010 (N125D, N156E) 160 160
Homologous titre (bold) is indicated.
aFerrets were infected with egg-grown A/Tasmania/200/2009 virus.
bSerum following a single immunization with MIV+IFA.
cN156K reverse genetics virus is not included as it could not be rescued.
doi:10.1371/journal.ppat.1003354.t005
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that the wildtype antiserum contains a high level of antibodies
directed towards the N156 region of the HA protein, whilst the
N156K and K142N+N156K antisera contains antibodies that are
directed towards a region of the HA protein, common to both
wildtype and N156K HA.
HA receptor specificity was assessed by binding of synthetic
multivalent glycans. Human influenza viruses have been shown to
bind predominantly to 69 sialyllactose (69SL) and 69 sialyllactosa-
mine (69SLN) and, to a lesser extent, to 39 sialyllactose (39SL), as
representatives of a-2,6- and a-2,3-linked Neu5Ac receptors
[28,41–45]. HA on the surface of cells infected with ferret adapted
A/Tasmania/2004/2009 wildtype virus bound to both 69SL and
69SLN (Figure 4C). Binding was more restricted compared to the
original egg inoculum virus, presumably due to the mutations
L191I and R223Q (Figure 4C). Introduction of the N156K
mutation to the ferret adapted virus resulted in binding to only
69SLN, indicating a strong preference for a-2,6-linked Neu5Ac
receptors containing GlcNAc rather than galactose (Figure 4C,
N156K, D14E+N156K, K142N+N156K). K142N and N156E
displayed a similar profile to N156K. K153E showed weak
binding to 69SLN, G155E showed binding to 69SL and 69SLN.
Addition of G155E to N156K increased 69SL binding, while the
addition of K153E to N156K did not alter the binding preference.
Predicted receptor binding properties and structural
analysis using 3-D modeling
Computer modeling with a-2,6- and a-2,3-linked Neu5Ac
receptors was performed to enable a structural basis for the
Figure 4. Analysis of antigenicity and glycan binding to HA on influenza virus-infected cells. MDCK-SIAT1 cells were inoculated with A/
Tasmania/2004/2009 egg-grown inoculum, ferret nasal wash (indicated by ‘) or rescued reverse genetics ferret-adapted viruses (indicated by ‘rg’) or a
control A(H3N2) egg-grown virus. After 48 h, cells were analysed for binding of (A) anti-HA mAbs, (B) post-immunization ferret antisera (MIV or
MIV+IFA) or post-infection ferret antisera (wildtype A/Tasmania/2004/2009, N156K or K142N+N156K virus) or (C) synthetic glycans. (B) To control for
differences in infection rate between wildtype and N156K viruses, antibody binding is expressed as the proportion relative to K142N+N156K
antiserum (% positive for test antiserum/% positive K142N+N156K antiserum). Mean+standard deviation of six paired experiments are shown for all
antisera except MIV+IFA which is calculated from three paired experiments. (C) Glycan binding is expressed as a proportion to itself ((mean
fluorescent intensity (MFI) with glycan-MFI without glycan)/MFI with glycan6100), for influenza A matrix positive cells only. Individual experiments
are shown by each symbol.
doi:10.1371/journal.ppat.1003354.g004
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N156K mutation and subsequent cell culture adaptations. The
computational results were also compared to the glycan binding
results (Figure S3A). N156K is at the interface of three previously
crystallized antibody binding sites [46–48] (Figure S3B). Since
amino acid mutations that involve charge changes can alter the
strength of the electromagnetic field around the HA globular head,
and long range electrostatic forces are often a first step to facilitate
interaction with ligands and other proteins, changes in the
electrostatic surface potential due to the observed mutations were
also analyzed.
Although position 156 is not in the receptor binding site, our
analysis suggests that small changes at this position influence HA
binding, stability and receptor specificity. The N156K mutation
noticeably adds positive charge potential compared to wildtype
HA (Figure 5A, B). In contrast, N156E significantly reconfigures
the distribution of charge (Figure 5C). N156K is predicted to
prefer a-2,6-linked receptors (Figure 5E), whilst in our models it
is more favorable for the N156E mutation to bind to a-2,3-linked
receptors (Figure 5E). Adding K153E to N156K reduces the
positive electrostatic potential of the HA head domain (Figure 5D)
as does the addition of G155E to N156K (Figure S3C). The
addition of K153E to N156K (and G155E to N156K) appears
compensatory, allowing stronger binding to a-2,3 receptors
compared to N156K alone (Figure 5F, Figure S3C,D).
However, this increased a-2,3 receptor binding was not evident
in the glycan binding studies that were undertaken (Figure 4C).
Discussion
This study is the first to describe the emergence of an
A(H1N1)pdm09 escape variant, with altered receptor binding,
following vaccine-induced immune pressure in a ferret model of
contact transmission. This N156K mutation was generated in two
independent lines of MIV+IFA-immunized ferrets, but was not
detected in the virus used to infect ferrets, nor did it appear in
unimmunized ferrets, suggesting that the N156K mutation had a
selective advantage when placed under non-sterilizing immune
pressure.
Virus fitness was investigated in the presence and absence of
immune pressure in this study. The N156K virus transmitted
between immunized ferrets for up to four passages, although a
break in transmission occurred in both lines. A break in
transmission in vaccinated animals has also been noted in an
artificial infection system of a laboratory influenza strain in mice
[13]. The investigation of virus kinetics under immune pressure is
unique to this ferret study. The emergence of the N156K virus did
not alter the virus kinetics in the MIV+IFA-immunised ferrets.
There was no change in peak viral load, growth rate or serial
interval between transmissions. This is likely a reflection of the in
vivo model system. Adjuvant has been shown to restrict and
broaden the immune response (reviewed by [49]), yet was
necessary to induce even a detectable immune response in the
ferret model [24]. The influence of a different adjuvant, or even a
background of immunological experience through previous
infection(s), may warrant further investigation. When passaged in
naı¨ve ferrets, the growth kinetics and transmission potential of the
N156K virus was equivalent to the wildtype virus, indicating that
the N156K mutation was not deleterious in non-immune ferrets.
The N156K virus outgrew the wildtype virus in both naı¨ve and
immunized ferrets when in direct competition, suggesting that the
N156K mutant is fitter than the wildtype virus in both the
presence and absence of immune pressure.
The interplay between antigenic drift and receptor binding
specificity and affinity has been well studied for the HA of
influenza viruses [13,16,50]. Due to the close proximity of the
antigenic sites to the receptor binding site, antigenic changes are
often accompanied by changes in the receptor binding properties
of the virus [13,15,16] and changes in receptor binding properties
can also produce antigenic variants [13]. Passage of influenza virus
under immune pressure in vivo may favor mutations that facilitate
antibody escape, but may also increase viral HA avidity for cell
surface receptors. Subsequent passaging in the absence of immune
pressure in vivo may induce compensatory mutations that reduce
avidity and can affect antigenicity [13]. Furthermore, mutations in
A(H1N1)pdm09 HA that change positive electrostatic charge have
been associated with changes in the affinity for Neu5Ac receptors
[16]. We have demonstrated that the N156K mutation produced
structural changes that altered receptor specificity, including the
loss of ability to agglutinate RBC from a variety of species.
Changes in hemagglutination patterns with different species’ RBC
have also been associated with antigenic drift of A(H3N2) viruses
[43,50]. The N156K mutation also increases the positive charge
potential, which may be important for surface interactions of the
HA protein with antibodies or more remote carbohydrate moieties
extending from the natural host receptor structure. The cell
culture adaptations, K153E and G155E, are predicted to induce
structural changes in the HA head that reduce the positive
electrostatic potential of the HA head domain. These changes
have been shown to reduce viral HA receptor binding avidity for
a-2,3- and a-2,6-linked Neu5Ac receptors in vitro [16]. Thus, we
hypothesize that the N156K mutation increases receptor binding
avidity compared to wildtype virus. When cultured in vitro, the cell
culture adaptations negate the significant effects of the N156K
mutation on the charge distribution and alter the receptor binding
preference of the HA protein (and possibly the avidity), which
facilitates hemagglutination. Attempts to assess the avidity of the
N156K and K142N+N156K mutants were unsuccessful due to
virus isolation difficulties and the inability of the viruses to bind
RBC. Interestingly subsequent passage of the N156K mutant virus
in naı¨ve ferrets did result in an additional mutation in the HA
protein, K142N, in one passage line. Although this double mutant
outgrew the N156K mutant in a competitive mixture in vivo, the
K142N mutation was not acquired in both lines of passaging
suggesting it is not essential for transmission in naı¨ve ferrets.
K142N did not alter receptor binding specificity in the assays used
in this study, but whether changes in avidity have occurred is
unknown. Overall, these data suggest that selection of the N156K
mutant, maintained through contact transmission in ferrets, drives
emergence of a virus with altered, but effective, binding to
receptors of the ferret respiratory tract, and is capable of extensive
replication in vivo. In vitro isolation difficulties indicate more
detailed analysis of receptors in the ferret respiratory tract and on
cell lines used for routine isolation of influenza virus may be
needed. As antiserum from a wildtype virus-infected ferret
appeared directed to the N156 region and could no longer
recognise the N156K mutant virus, and antiserum from a N156K
virus-infected ferret appeared directed to a different region of the
HA common to wildtype and N156K mutant virus, we
hypothesize that immunity is directional and drives antigenic drift
in this contact transmission model. We anticipate that further
passage of the N156K mutant virus in homologous vaccinated
ferrets (i.e vaccinated with the N156K mutant) would drive further
drift of the A(H1N1)pdm09 N156K virus that would be again
accompanied by changes in the receptor binding properties.
Although a pure population of the N156K mutant virus could
not be efficiently isolated, either from ferret nasal washes or by
reverse genetics, flow cytometry antibody binding assays demon-
strated that the N156K mutation causes antigenic escape. This is
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supported by the following additional evidence: The N156K
mutant arose only in ferrets with specific antibodies, and was
present in both passage lines. The N156K mutant virus could not
be recognized by a monoclonal antibody (mAb174) which drives
escape in the Sa/Sb antigenic site of wildtype virus. N156K is
computationally predicted to be structurally significant by
introduction of a longer charged side chain that changes the
distribution of the charge of the HA. Analysis of influenza vaccine
strains over time has demonstrated that charge mutations also
contribute to antigenic drift (unpublished data, S. Maurer-Stroh
and R.T.C. Lee). Alternate mutations at this position, N156E and
N156D, have been shown to cause antigenic changes [16,51].
Other published in vitro studies have found mutations at similar
sites in the HA protein of A(H1N1)pdm09 viruses ( amino acids
Figure 5. 3-D modeling of HA containing N156K and cell culture adaptations. (A–D) Comparison of electrostatic surface potential of
wildtype and single and pair mutations in the HA head domain, calculated with the Particle Mesh Ewald method implemented in YASARA. Blue
indicates positive and red indicates negative charge potential. A host receptor analogue is shown in magenta. (E,F) Structural modeling of single and
pair mutations in HA with bound a-2,6- or a-2,3-linked host receptor ligands. (E) Model of N156 wildtype (green HA/yellow ligand), N156K (cyan HA/
red ligand) and N156E (blue HA/purple ligand) shown with a-2,3 host receptor analogue. (F) Comparison of N156 wildtype (green HA/yellow ligand)
and N156K (cyan HA/red ligand) with double mutant K153E+N156K (light blue HA/orange ligand).
doi:10.1371/journal.ppat.1003354.g005
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143–146, 148, 153–156, 204) [15,16,29,40] which also affected
antigenicity; however interpretation of these in vitro experiments is
complicated by the different culture conditions and selection
pressures employed. Changes can also occur at amino acid
positions 153 and 155 in the A(H1N1)pdm09 HA without any
immune selection pressure [29], suggesting an instability in this
region during cell culture. No changes have been reported at 156
in the A(H1N1)pdm09 HA experimentally without immune
pressure. However, monoclonal antibodies from humans and
mice (this study and [15,16]), and polyclonal ferret antibodies
raised in this study, all targeted similar regions. This suggests that
amino acids 153–156 form an immunodominant region of the HA
protein and targeting this area results in a significant antigenic
change.
A(H1N1)pdm09 viruses with mutations at position 156 have
been reported in human surveillance studies ([40], WHO
Collaborating Centre for Reference and Research on Influenza,
Melbourne), although they occur relatively rarely (0.15% of all
samples on GISAID with passage information). We have
demonstrated that this mutation from ferret respiratory samples
does not persist in cell culture without further adaptation, or
reversion to wildtype virus in mixed populations. The low HA titre
in the initial passage, and negative association with cell culture,
may prevent identification of original clinical samples containing
N156K alone, hence laboratories may exclude these viruses from
surveillance studies. Therefore conventional methods for isolation
of human samples may select against detection of mutations at
position 156. We also cannot discount the possibility that the ferret
model has selected for a mutant that has compromised transmis-
sibility in the human population, due to differences in the glycan
receptor profiles between the human and ferret respiratory
tract, or more complex immunity in humans with their
extensive infection and vaccination history. Use of a different
A(H1N1)pdm09 strain, cell-cultured virus or an alternate
adjuvant/vaccine preparation may have also influenced the
mutation profile. Further analysis of viruses from the lungs of
MIV-immunized ferrets, where immune escape mutants may also
emerge, would be worthwhile.
A(H1N1)pdm09 has circulated over the past four years with
limited genetic diversification and no significant antigenic change.
Rising population immunity is likely to drive antigenic drift in the
A(H1N1)pdm09 virus eventually. Passage in immune ferrets
demonstrated that an antigenic mutant can arise in a similar
situation. Importantly, antigenic mutations in the HA may also
influence receptor binding properties, affecting the efficiency of
isolation of viruses for surveillance characterization purposes.
Routine genetic analysis of original clinical specimens is therefore
important. In vitro and/or in vivo passage of the 2012/2013
A(H1N1)pdm09 viruses under immune pressure would indicate
whether N156K is permissive in the presence of additional
mutations or whether other regions of the HA globular head are
now under greater selective pressure. Continued examination of
influenza virus escape mutants should aid in the identification of
future vaccine-breakthrough viruses, enabling their rapid detection
through influenza surveillance and ensuring appropriate changes
to the A(H1N1)pdm09 component of seasonal influenza vaccine
are made in a timely fashion.
Materials and Methods
Ferrets
Male and female ferrets (weight, 500–1500 g) were purchased
from independent breeders and housed at CSL Limited using
services provided under a Support Services Agreement. Serum
samples from ferrets were tested by HI assay to ensure
seronegativity (titre ,20) to currently circulating influenza strains
before use. Experiments using ferrets were conducted with
approval from the CSL Limited/Pfizer Animal Ethics Committee,
in accordance with the Australian Code of Practice for the Care
and Use of Animals for Scientific Purposes.
Viruses and cells
A/Tasmania/2004/2009 virus was isolated from an elderly
patient who succumbed to influenza infection in July 2009, as part
of routine influenza surveillance activities at the WHO Collabo-
rating Centre for Reference and Research on Influenza,
Melbourne. The sample was anonymized. Viruses were passaged
in the allantoic cavity of embryonated hen’s eggs and MDCK-
SIAT1 cells and stored at 280uC. MDCK (CCL-34:ATCC) and
MDCK-SIAT1 cells (kindly provided by Hans-Dieter Klenk,
University of Marburg, Marburg, Germany) were maintained as
previously described [52], in the absence of G418 sulphate. A549
and Vero cells were maintained in the same conditions as MDCK
cells. BEAS-2B cells (kindly provided by Dr R. Gualano The
University of Melbourne, Melbourne, Australia) were maintained
in 1:1 (v/v) RPMI 21640 (SAFC Biosciences) supplemented with
10% [v/v] FCS, 50 U/ml penicillin, 50 mg/ml streptomycin
(SAFC Biosciences): BEGM with BulletKit (Cambrex, Clonetics,
USA). Cells were maintained at 37uC, 5% CO2 prior to infection
and following infection, unless indicated.
Vaccine formulation and administration
Full or half adult doses (15 mg or 7.5 mg HA in 0.5 mL,
respectively) of human monovalent A(H1N1)pdm09 influenza
vaccine containing the HA and NA of A/California/7/2009
(MIV) (Panvax, a gift from CSL Limited) were used for
immunization. Ferrets were immunized with MIV alone or MIV
emulsified in an equal volume [1:1 (v/v)] Freund’s Incomplete
Adjuvant (IFA) (Sigma-Aldrich) immediately before administration
(1 ml total volume) (MIV+IFA). Control ferrets were immunized
with PBS emulsified in IFA (1 ml total volume) (PBS+IFA) or did
not receive vaccine (naı¨ve). Adjuvanted vaccines were delivered to
anaesthetized animals (0.2 mL/kg, 1:1 [v/v] Ilium Xylazil-
20:Ketamil, Troy Laboratories) intramuscularly in the quadriceps
muscles of both hind legs using a 1-mL syringe with a 22-gauge
needle. Animals received one dose of MIV+IFA or PBS+IFA or
two doses of MIV two weeks apart. Vaccinated animals were used
24 to 94 days after the final immunization. Serum was collected
before and after each vaccination, immediately before ferrets were
included in the contact transmission passaging and at sacrifice.
Virus infection of donor ferrets and passaging of virus by
contact transmission
Naı¨ve donor ferrets (termed Donor 0; D0) were anaesthetized
and infected artificially by intranasal inoculation with 103.5 50%
tissue culture infectious doses (TCID50) egg-grown influenza virus.
After inoculation, D0 ferrets were housed individually in a HEPA-
filtered isolation unit. The following day, two naı¨ve ferrets (both
termed Donor 1; D1) were co-housed with each D0 ferret and
remained in continual contact, until they became naturally
infected with influenza virus (see below). Once a D1 ferret was
found to be infected it was placed in a separate clean cage, to then
infect the first ferret of a passage line. Naı¨ve donor ferrets (D0 and
D1) were used to establish a transmission chain as previous studies
have indicated that direct inoculation of in vitro cultured virus can
alter viral diversity within a host [53]. Four different D0 ferrets
infected seven different D1 ferrets, each D1 ferret was assigned to
Antigenic Drift of A(H1N1)pdm09 Virus in Ferrets
PLOS Pathogens | www.plospathogens.org 13 May 2013 | Volume 9 | Issue 5 | e1003354
start one (or two) passage lines (as indicated in Figure 1 and S1).
Each line involved sequential passage of virus through eight
recipient ferrets that had received one of three different treatments
(MIV+IFA, MIV, PBS+IFA) or no treatment (naı¨ve). The first
recipient ferrets from each immunization group (R0) were co-
housed with one of the D1 ferrets until they became naturally
infected. 24 hours after the viral load measurement from each R0
ferret indicated that they were infected, the R0 ferret was co-
housed with the next recipient ferret (R1) from their line.
Transmission experiments continued for each immunization
group until seven passages had been completed (R0 to R7).
Duplicate lines were performed for each immunization group,
designated line A and line B. Ferrets were sacrificed and
respiratory tissues and serum were collected after they had
successfully transmitted the virus to the new recipient ferret. The
recipient order for the passage lines was randomly assigned in each
immunization group, irrespective of HI antibody titre following
immunization, or days since immunization.
Detection of virus infection in ferrets
Nasal washes were collected daily under light sedation (30 mg/
kg Ilium Xylazil-20; Troy Laboratories) by delivery of 1 ml PBS
supplemented with 50 U/ml penicillin, 50 mg/ml streptomycin
(SAFC Biosciences) and 1% w/v BSA (Sigma-Aldrich) into the
nostril. Expelled liquid was collected and 140 ml was aliquoted for
RNA extraction (see below) and real time RT-PCR analysis, 60 ml
for TCID50 analysis, 30 ml for rapid test analysis and the
remainder stored at 280uC. Animals were weighed and visually
inspected daily and their temperature was measured using
implanted temperature transponders fitted to identification chips
(LifeChip Bio-Thermo, Digivet). Daily nasal wash samples were
assessed for virus shedding as a measure of infection by rapid test
analysis (BD Directigen EZ Flu A+B kit, Becton Dickinson) or by
real time RT-PCR analysis of extracted RNA for matrix 1 gene.
Transmission was deemed to have occurred when the new
recipient ferret returned a positive rapid test, or a positive real time
RT-PCR result (Ct#25).
Real time RT-PCR
RNA was extracted from nasal washes, cell culture supernatants
or allantoic fluid using the QIAamp Viral RNA Mini Kit (Qiagen).
An 8 ml aliquot of RNA was treated with RNAse Free DNase I
(New England Biolab) in a total reaction volume of 10 ml,
according to the manufacturer’s instructions. DNase-treated RNA
(4 ml ) was used to amplify influenza A matrix 1 using CDC
Atlanta (USA) InfA F primer and InfA probe [54] and modified
InfA R primer (59GGGCATTYTGGACAAAKCGTCTACG39)
with SuperScript III Platinum One-Step qRT-PCR kit (Invitro-
gen). The RT-PCR consisted of 1 cycle of 50uC for 5 min and
95uC for 2 min and 40 cycles of 95uC for 3 s, 60uC for 30 s using
the 7500 Fast Real-Time System (Applied Biosystems) and 7500
Fast System SDS Software version 1.4.0. The threshold was
automatically set and Ct determined. RNA standards were
prepared from pGEMT-A/California/7/2009 and pGEMT-A/
Perth/16/2009 Matrix plasmids using the Riboprobe In Vitro
Transcription Systems (Promega). For all runs, samples (assayed in
duplicate), no-template control, RNA standards and positive and
negative controls were included. The 95% confidence interval for
RNA standards was 0.78 Ct (n = 65 assays). The detection limit
was 10 copies.
Preparation of cDNA for genetic analysis
cDNA was synthesized from 5 ml RNA isolated from ferret nasal
wash (peak day of infection), cell culture supernatants or allantoic
fluid, using the SuperScript III First-Strand Synthesis SuperMix
(Invitrogen), with Uni12 primer [55], according to the manufac-
turer’s instructions. cDNA generated from ferret nasal wash was
sequenced, used in pyrosequencing assays, or amplified by PCR
and cloned.
Genetic sequencing
Viral genes were amplified from cDNA or DNA plasmids (see
below) using MyTaq HS Mix (Bioline) with M13 tagged-gene-
specific primers ([56] and WHO Collaborating Centre for
Reference and Research on Influenza, Melbourne – sequences
available upon request) or plasmid-specific primers, according to
the manufacturer’s instructions. Unincorporated primers and
dNTPs were removed using ExoSAP-IT (Affymetrix), according
to the manufacturer’s instructions. DNA sequencing was per-
formed with M13 primers (M13F-59 TGTAAAACGACGGC-
CAGT and M13R 59 CAGGAAACAGCTATGACC) or plasmid-
specific primers in a 96-well plate format using the BigDye
Terminator v3.1 Cycle Sequencing Kit (Life Technologies),
followed by the removal of excess dye terminators with a BigDye
XTerminator purification kit (Applied Biosystems). The sequence
was determined using an automated capillary DNA sequencer
(ABI Prism 3500xL). Identification of mixed bases was set at 25%.
Sequences were assembled using DNASTAR Lasergene Suite
v.9.1.0 Seqman v 9.1.
Nucleotide sequence accession numbers
The nucleotide sequences for all segments of A/Tasmania/
2004/2009 egg-grown virus inoculum are available from the
GISAID public database under accession number
EPI_ISL_129743. A/California/7/2009 sequences used in this
study were from GenBank: CY058519, GQ214336, CY121681,
GQ338390, CY121684, CY121685, GQ323558, FJ984387.
Generation of DNA plasmids
The HA1 gene of A/Tasmania/2004/2009 virus from cDNA
generated from ferret nasal wash was amplified using gene-specific
primers and cloned into pGEM-T Easy vector (Promega)
according to the manufacturer’s instructions. For reverse genetics,
the entire HA and NA genes of A/Auckland/1/2009
(A(H1N1)pdm09) virus [24] were amplified from cDNA generated
from a clinical specimen using ThermoScript RT-PCR System
(Invitrogen) using primers containing BsmBI and BsaI sites
respectively, and cloned into pHW-2000 vector [57] according
to the manufacturer’s instructions. S203T, Q223R and H496N
were introduced into the HA gene to generate pHW-2000-A/
Tasmania/2004/2009 HA vector. L191I and R223Q were then
introduced to generate ferret-adapted pHW-2000-A/Tasmania/
2004/2009 HA vector. S388T was introduced into the NA gene
to generate pHW-2000-A/Tasmania/2004/2009 NA vector.
Further mutations and adaptations were introduced as indicated
in the text. Mutations were introduced using the QuikChange II
Site-Directed Mutagenesis kit (Strategene) with the QuikChange
Primer Design Program.
Pyrosequencing assay to quantify the proportion of the
wildtype, N156K or K142N+N156K mutants
Two separate pyrosequencing assays were utilized. The first
quantified the proportion of the N156 (wildtype) vs the N156K
mutant (WT/N156K). The second assay quantified the proportion of
K142 vs K142N mutant (N156K/K142N+N156K). A 350 bp region
of the HA1 gene flanking amino acid positions 142 and 156 was
amplified from plasmid mixtures and from cDNA from ferret peak day
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nasal wash samples using MyTaq HS Mix (Bioline) with biotinylated
forward primer (59Biotin-GCAATTGAGCTCAGTGTCATC) and
reverse primer (59TTCCGGCTTGAACTTCTTGC) (for the WT/
N156K assay) or forward primer (59GCAATTGAGCTCAGTGT-
CATC) and biotinylated reverse primer (59Biotin-TTCCGGCT-
TGAACTTCTTGC) (for the N156K/K142N+N156K assay), ac-
cording to the manufacturer’s instructions. The pyrosequencing
reaction was performed as previously described [58], using internal
primers 59GGATTTGCTGAGCTTTGGGT and 59CTCATGC-
TGGAGCAAA, specific for the N156K and K142N mutations,
respectively. The proportions of N156 and K156, or K142 and N142,
HA in the sample, were estimated by calculating the ratio of the two
peaks representing the N156 and K156, or K142 and N142 HA, using
the AQ mode in the PyroMark ID 1.0 software. The N156K mutation
generates a quadruplicate run of adenosines, which does not quantify
absolutely by this technology [59–61], thus the detection limit was 5–
10% for N156K. To correct for the sensitivity of the assay, all nasal
wash samples were run with a set of plasmid mixtures containing
various ratios. Mixtures of pGEMT plasmids with A/Tasmania/
2004/2009-HA1 and A/Tasmania/2004/2009-HA1-N156K or A/
Tasmania/2004/2009-HA1-N156K and A/Tasmania/2004/2009-
HA1-K142N+ N156K inserts were prepared at different molar ratios
(100:0, 80:20, 50:50, 20:80, 0:100), at multiple concentrations (1, 0.1,
0.001 pg total). A standard curve was generated using the plasmid
mixtures and the proportion of N156/K156 or K142/N142 in each
nasal wash sample was determined by comparison to a standard curve.
All samples were run in triplicate.
Analysis of variants by cloning
The HA1 gene was amplified from cDNA generated from ferret
nasal washes or egg-grown A/Tasmania/2004/2009 using the
Velocity PCR kit (Bioline) with M13 tagged-HA1-specific primers
(as above). Amplified product of the correct size was purified using
the E-Gel CloneWell system (Invitrogen) and cloned using the
Zero Blunt TOPO Cloning Kit for Sequencing (Invitrogen). DNA
from 96 individual colonies with confirmed HA insert was
sequenced for all samples except the initial inoculum for which
480 colonies were sequenced. HA1 was amplified using MyTaq
HS Mix (Bioline) and A/Tasmania/2004/2009 HA1-specific
primers ((F 59 TAGTTCTGCTATATACATTTGCAACCG,
R-59GGATGTATATTCTGAAATGGGAGGC) then sequenced
using the same primers. Poor quality sequences were excluded
from the data set. As a control, the pGEMT-A/Tasmania/2004/
2009 HA1 plasmid was transcribed using the Riboprobe In Vitro
Transcription Systems (Promega), cDNA synthesized as above,
then the HA1 gene amplified and cloned; 96 individual colonies
were sequenced. The error rate in the amplification system, as
determined by sequencing 96 clones from a single plasmid, was
less than 0.001%.
Reverse genetics rescue of influenza A viruses
Engineered viruses were generated as previously described [57],
with infectious virus detected by hemagglutination and real time
RT-PCR of culture supernatants. All viruses contained the HA
and NA from ferret-adapted A/Tasmania/2004/2009 including
specified mutations, whilst the remaining genes were from
A(H1N1) A/Puerto Rico/8/1934 (pHW2000-A/Puerto Rico/8/
1934 vectors, a kind gift from St Jude Children’s Research
Hospital, Memphis, TN, USA) or A(H1N1)pdm09 A/Perth/261/
2009.
Virus infection of cell cultures and analyses
Cells were seeded into T25 flasks or 24-well tissue culture plates
and grown to confluence overnight. Monolayers were washed
twice with Ca2+/Mg2+-free phosphate-buffered saline before
incubation with 500 or 100 ml virus, respectively (nasal wash
samples inoculated at 1/6 to 1/10 dilution; cell culture isolates
inoculated neat; egg-grown virus inoculated at 1/100) at 37uC and
5% CO2 for 30 min, or other temperatures, as indicated. The
inoculum was removed and replaced with medium (without fetal
calf serum) supplemented with 4 mg/ml trypsin (Sigma) [52].
2 mU/ml exogenous neuraminidase (from Clostridium perfrin-
gens (Sigma) or 5 nM oseltamivir carboxylate (the active form of
the ethyl ester prodrug oseltamivir phosphate, kindly provided by
Hoffmann-La Roche Ltd, Switzerland) was added to cultures as
indicated in the text. Supernatant was collected daily and the
presence of virus was assessed by hemagglutination using 1%
turkey RBC and by real time RT-PCR assays for the influenza A
matrix gene. Infection was also assessed by surface staining of
infected cells and analysis by flow cytometry. Cells were stained
with anti-influenza A HA monoclonal antibodies (mAbs)
(A(H1N1)pdm09: mAb174 clone 10F5.1D7 and mAb175 clone
2G10.1C11; A(H3N2): mAb131 clone 4E4.1F10 and mAb 132
clone 1G6.1G7; kindly provided by CSL Limited), ferret antisera,
followed by anti-ferret Ig-FITC (Rockland Immunochemicals Inc.,
USA) or anti-influenza A matrix mAb (clone GA2B, AbD Serotec,
UK), followed by anti-mouse Ig-FITC (SantaCruz Biotechnology
and KPL). Staining was performed in the presence of 1 mM
oseltamivir carboxylate. Samples were run on a FC500 Analyzer
(Beckman Coulter) or FACSCanto II (BD Biosciences) with data
analysis using FlowJo 7.5.5 software.
Flow cytometry-based glycan binding assay
The binding specificity of influenza HA was determined using
an assay previously described [41]. Briefly, MDCK-SIAT1 cell
monolayers, in 24-well plates, were infected with the same copy
number of influenza virus from different ferret nasal washes, or
reverse genetics viruses. After 48 h, cells were harvested, washed
three times with PBS and stained with biotinylated multivalent
glycans (5 mg/ml) and mouse anti-influenza A matrix mAb in PBS,
with 1 mM oseltamivir carboxylate for 2 h at 4uC. Glycans,
Neu5Aca2-6Galb1,4GlcNAc-PAA-biotin (69 sialyllactosamine;
69SLN), Neu5Aca2-3Galb 1,4Glc-PAA-biotin (39 sialyllactose;
39SL) and Neu5Aca2-6Galb 1,4Glc-PAA-biotin (69 sialyllactose;
69SL), were purchased from GlycoTech (MD, USA). To detect
biotinylated glycan binding, cells were incubated with streptavidin-
RPE (Vector Laboratories, USA) and mouse mAb was detected
with anti-mouse Ig-FITC in PBS with 1 mM oseltamivir carbox-
ylate, for 1 h at 4uC. Samples were analysed by flow cytometry.
Cell culture supernatant was also collected upon cell harvest and
assessed by real time RT-PCR and hemagglutination. HA and NA
genes were sequenced to ensure no adaptations had occurred.
Hemagglutination Inhibition (HI) assay
Reactivity of serum samples was measured using HI assays [62]
as described elsewhere [63]. Titres were expressed as the
reciprocal of the highest dilution of serum for which hemagglu-
tination was prevented. GMT was calculated with undetectable
titres expressed as ‘5’. Seroconversion was defined as titre $40.
Statistics
Viral growth kinetics were assessed using real time RT-PCR
data. Animals artificially infected by intranasal inoculation were
excluded from the analysis. The virus growth rate was calculated
as the difference between viral copy number between the peak day
and the first day, divided by the number of days to reach peak viral
copy number. Animals for which viral load peaked on day 1 were
excluded. The serial interval between transmission was defined as
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the number of days between virus detection in the infecting and
infected ferret. Only transmission events where both animals were
deemed infected using the same method of detection were
included. Transmission events involving artificially inoculated
animals or interruptions (see results) were excluded. Data were
analysed using one-way ANOVA, and Bonferonni correction to
adjust for multiple comparisons, using STATA. Ferret antisera
binding to virus-infected cells was analyzed by comparing the
relative proportion from wildtype and N156K-infected cells for
each antiserum using Spearman’s rank correlation co-efficient.
Statistically significant results are indicated with * p,0.05,
** p,0.01 and *** p,0.005.
Analysis of frequency of mutations in human clinical
specimens on GISAID and Genbank
All A(H1N1)pdm09 HA sequences from viruses isolated from a
human host since 2009 were downloaded from GISAID and
GenBank, and filtered to remove strains occurring multiple times.
The resulting 16740 sequences were aligned using MAFFT [64].
To determine whether a mutation preferentially occurred in a
culture type, sequences with passage history were classified into
four categories based on the source from which they were
extracted and sequenced: (i) embryonated hen’s egg, (ii) MDCK
cells, (iii) MDCK-SIAT1 cells and (iv) original clinical sample. The
odds ratios were calculated from the probabilities of occurrence of
the mutant and the wildtype in each of the source cell types. The
degree of association of the mutants to the source cell types were
classified into 5 categories: (i) moderate association (1.5–3), (ii)
strong association (.3.0), (iii) moderate negative association (0.33–
0.66), (iv) strong negative association (,0.33) and (v) no association
(0.66–1.5) [65].
3-D modeling
Simulated annealing energy minimizations through short
molecular dynamics (MD) simulations using the AMBER03 force
field in YASARA were done for wildtype and mutant HAs in
complex with either a-2,3 or a-2,6 ligand (PDBs: 3ubj chains C
and D or 3ube chains A and B, respectively [66]. For structural
correspondence, only the sialic acid and the first bound galactose
of the ligands were kept. The ligands were parameterized
automatically by YASARA [67]. YASARA has been previously
shown to provide excellent results in the CASP competition for
homology model refinements [68]. The used minimization
protocol comprises the following steps: in short, to remove bumps
and correct the covalent geometry, the structure was energy-
minimized with the AMBER03 force field [69], using a 7.86431
Angstroem force cutoff and the Particle Mesh Ewald algorithm
[70] to treat long-range electrostatic interactions. After removal of
conformational stress by a short steepest descent minimization, the
procedure continued by simulated annealing (time step 2 fs, atom
velocities scaled down by 0.9 every 10th step) until convergence
was reached, i.e. the energy improved by less than 0.05 kJ/mol
per atom during 200 steps. Counterions are implicitly considered
by setting the net charges to 0. Solvation is also considered
implicitly by a term proportional to the accessible surface area.
1.2 kJ/mol was used as the estimate for the entropic cost of
exposing one square Angstroem to the solvent. To further reduce
the computational complexity and potential unrelated simulation
bias, atoms further than 8 Angstroem from either the ligand or the
respective mutated residues were fixed (not allowed to move). This
resulted in a system of both flexible ligand and flexible receptor
binding pocket. The relative binding energies were estimated
through a function considering standard potential energy terms
plus the above mentioned implicit solvation. Three steps of
sequential forward and backward mutations for each mutation set
were employed and averaged over the visited energy minima.
Finally, for each analyzed single or pair mutation(s) we subtracted
the predicted energy for binding the a-2,6 receptor from the
predicted energy for binding the a-2,3 receptor. Higher values of
the measure therefore indicate a-2,6 preference while lower values
would point to relative a-2,3 preference. In order to compare the
predicted measure with the experimental glycan binding data (see
above), we derived a corresponding relative preference value by
subtracting the mean fluorescence intensity of glycan expression
for 39SL from the average for 69SL and 69SLN for the respective
mutation(s). The subtraction order of experimental receptor data
was inversed to obtain a direct linear correlation with the
computational measure.
Supporting Information
Figure S1 Time course of influenza transmission
through B passage lines. A separate D0 and D1 ferret
established the passage line B of the naı¨ve experimental group.
Similarly, a separate D0 and D1 ferret established passage line B of
the MIV experimental group. The same D0 ferret infected two
different D1 ferrets to establish the passage line B of the PBS+IFA
and MIV+IFA experimental groups. Nasal washes were collected
daily from ferrets and virus load measured by real time RT-PCR.
During the experiment, both the rapid test result (PBS+IFA,
MIV+IFA day 0–26) and the raw Ct value (naı¨ve, MIV, MIV+IFA
day 27 onwards) was used as a marker of infection and
transmission. The data points whereby transmission of virus to
recipient ferrets were deemed to have occurred are identified as
red symbols. Direct intranasal inoculation (arrow).
(TIF)
Figure S2 Time course of N156K mutant influenza virus
transmission through naı¨ve ferrets. R0–R7 ferrets from
lines A and B are identified. Nasal washes were collected daily
from ferrets and virus load measured by real time RT-PCR assay.
During the experiment, the raw Ct value was used as a marker of
infection and transmission. The data points whereby transmission
of virus to recipient ferrets were deemed to have occurred are
identified as red symbols. Direct intranasal inoculation (arrow).
(TIF)
Figure S3 3-D modeling of structure and interactions
around HA position 156. (A) Linear correlation of experi-
mentally measured and computationally predicted relative a-2,6-
to a-2,3-linked receptor preference, R2 = 0.72 (B) Position 156
(red) on the HA head domain (gray) is at the crossing of 3
previously crystallized antibody binding interfaces (cyan-antibody
to 1918 A(H1N1) PDB:3lzf [48]; yellow-antibody to A(H3N2)
PDB:2vir [47]; green-antibody to A(H3N2) PDB:1ken [46]. (C–
D) 3-D modeling of HA containing G155E+N156K. (C)
Electrostatic surface potential in the HA head domain, calculated
with the Particle Mesh Ewald method implemented in YASARA.
Blue indicates positive and red indicates negative charge
potential. A host receptor analogue is shown in magenta. (D)
Structural modeling of single and pair mutations in HA with
bound a-2,6- or a-2,3-linked host receptor ligands. Comparison
of N156 wildtype (green HA/yellow ligand) and N156K (cyan
HA/red ligand) with double mutant G155E+N156K (purple
HA/gray ligand).
(TIF)
Table S1 HA1 genetic variation within individual nasal
wash samples and virus inoculum by cloning analysis.
Variation compared to the original egg inoculum consensus
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sequence and number of times mutation detected (#) is indicated.
Bold mutations were detected in $4% of colonies sequenced.
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